EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

SGLT2 Inhibitors Associated With Improved Kidney Function in Lithium‐Treated Patients With Mood Disorders: A Real‐World Historical Cohort Study

Mete Ercis, Idil Tarikogullari, Vanessa K Pazdernik, Maria L Gonzalez Suarez, Raman Baweja, Alessandro Miola iD, Osama A Abulseoud, Jonathan G Leung iD, Susan L McElroy, Alfredo B Cuellar-Barboza, Michael J Gitlin, Aysegul Ozerdem und 2 weitere

Bipolar Disorders · 2026-03 · 28 (2)

DOI: 10.1111/bdi.70094 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Bipolar Disorders, online erschienen am 27.02.2026. Verfasst von Mete Ercis und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Glomerular Filtration Rate, Sodium-Glucose Transporter 2 Inhibitors, Antimanic Agents, Mood Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences (NCATS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), initially developed for type 2 diabetes, have shown promise in improving renal outcomes in patients with and without diabetes. However, their effect on lithium‐associated kidney dysfunction remains unknown.

Methods

This historical cohort study included patients from Mayo Clinic (2001–2023) with mood disorders who received lithium for ≥ 6 months and later used SGLT2i for ≥ 1 month. Data on SGLT2i use and lithium treatment were extracted from electronic health records. Serum creatinine values were used to calculate estimated glomerular filtration rate (eGFR) trajectories. Linear mixed‐effects models with piecewise linear splines were used to estimate eGFR slopes before and after SGLT2i initiation, adjusted for age and sex.

Results

Fifty‐six patients (mean age 57.4 years, 46.4% female), predominantly with bipolar disorder (87.5%), were included. The mean eGFR, measured nearest to SGLT2i initiation, was 77.9 ± 26.0 mL/min/1.73 m 2 , and the mean duration of SGLT2i use was 19.5 ± 17.8 months. Before SGLT2i initiation, eGFR declined at a rate of −1.43 mL/min/1.73 m 2 per year ( p < 0.001). After initiation, eGFR increased by 0.69 mL/min/1.73 m 2 per year, reflecting a + 2.13 change ( p = 0.025). Sensitivity analyses, including only patients on lithium at SGLT2i initiation ( n = 22) or who had > 1 year of SGLT2i use ( n = 29) showed similar, though non‐significant, changes in slopes.

Conclusion

SGLT2i treatment was associated with a significant improvement in eGFR trajectory in patients with mood disorders who received long‐term lithium therapy. These findings suggest a potential role for SGLT2is in mitigating lithium‐associated kidney dysfunction and highlight the need for randomized controlled trials in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerular Filtration RateSodium-Glucose Transporter 2 InhibitorsAntimanic AgentsMood DisordersBipolar DisorderLithium CompoundsKidneyLithiumHumansFemaleMiddle AgedMaleCohort StudiesAgedCreatinine

Stichwörter der Autor:innen

bipolar disordercreatininekidneylithiummood disorderssodium‐glucose transporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsAntimanic AgentsLithium CompoundsCreatinineLithium

Autor:innen und Institutionen

  • Department of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Psychiatry and Behavioral Health, Pennsylvania State College of Medicine, Hershey, Pennsylvania, USA.
  • Department of Public Health Sciences, Pennsylvania State College of Medicine, Hershey, Pennsylvania, USA.
  • Department of Neuroscience, University of Padova, Padua, Italy.

ORCID-Profile: Alessandro Miola, Jonathan G Leung, Mark A Frye, Balwinder Singh

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences (NCATS)

Zitieren

APA

Ercis, M., Tarikogullari, I., Pazdernik, V. K., Gonzalez Suarez, M. L., Baweja, R., Miola, A., Abulseoud, O. A., Leung, J. G., McElroy, S. L., Cuellar-Barboza, A. B., Gitlin, M. J., Ozerdem, A., Frye, M. A., & Singh, B. (2026). SGLT2 Inhibitors Associated With Improved Kidney Function in Lithium‐Treated Patients With Mood Disorders: A Real‐World Historical Cohort Study. Bipolar Disorders, 28(2). https://doi.org/10.1111/bdi.70094

Vancouver

Ercis M, Tarikogullari I, Pazdernik VK, Gonzalez Suarez ML, Baweja R, Miola A, et al. SGLT2 Inhibitors Associated With Improved Kidney Function in Lithium‐Treated Patients With Mood Disorders: A Real‐World Historical Cohort Study. Bipolar Disorders. 2026;28(2). doi:10.1111/bdi.70094

BibTeX
@article{Ercis2026,
  author = {Ercis, Mete and Tarikogullari, Idil and Pazdernik, Vanessa K and Gonzalez Suarez, Maria L and Baweja, Raman and Miola, Alessandro and Abulseoud, Osama A and Leung, Jonathan G and McElroy, Susan L and Cuellar-Barboza, Alfredo B and Gitlin, Michael J and Ozerdem, Aysegul and Frye, Mark A and Singh, Balwinder},
  title = {SGLT2 Inhibitors Associated With Improved Kidney Function in Lithium‐Treated Patients With Mood Disorders: A Real‐World Historical Cohort Study},
  journal = {Bipolar Disorders},
  year = {2026},
  volume = {28},
  number = {2},
  doi = {10.1111/bdi.70094}
}
Kostenlos starten →